{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:12:21Z","timestamp":1780578741094,"version":"3.54.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Farma, S.A.U. The company"},{"name":"APICES. Roche Farma S.A.U."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>BladderGATE evaluated the safety, tolerability, and efficacy of intravenous (IV) atezolizumab combined with intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in patients with BCG-na\u00efve high-risk non-muscle invasive bladder cancer (NMIBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a phase Ib\/II open-label, nonrandomized, dose de-escalation clinical trial of atezolizumab (1200\u2009mg IV infusion on day 1 of each 21-day cycle) plus BCG (1 instillation\/week) with an induction treatment period of 6\u2009weeks, followed by a maintenance treatment period of 52\u2009weeks maximum. During induction, dose-limiting toxicity (DLT) and maximum tolerated dose of atezolizumab were determined. The primary study outcome was recurrence-free survival (RFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 36 patients with high-risk NMIBC with a median age of 70\u2009years were enrolled in this study. Twenty participants completed the whole treatment schedule. No DLTs were recorded during the study period. The median RFS was not reached; RFS rates were 83% (95% CI 70.6%-95.4%) and 73% (95% CI 57.4%-88.2%) at the end of the first and second year, respectively. The incidence of serious drug-related adverse events was low. Additionally, no impairment in Health-related quality of life status throughout the study was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IV atezolizumab plus intravesical BCG in high-risk BCG-na\u00efve NMIBC patients resulted in a high RFS rate and a manageable safety profile. These results appear consistent with those of the ALBAN study, which did not demonstrate a significant benefit of this combination over BCG alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag177","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:40:03Z","timestamp":1778067603000},"source":"Crossref","is-referenced-by-count":0,"title":["The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib\/II BladderGATE clinical trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-3465","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"first","affiliation":[{"name":"Department of Urology, Hospital Universitario 12 de Octubre , Avda. C\u00f3rdoba S\/N , Madrid, 28041,","place":["Spain"]},{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"G\u00f3mez-Ca\u00f1izo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario 12 de Octubre , Avda. C\u00f3rdoba S\/N , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-Izquierdo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario 12 de Octubre , Avda. C\u00f3rdoba S\/N , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-2936","authenticated-orcid":false,"given":"Mario","family":"Hern\u00e1ndez-Arroyo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario 12 de Octubre , Avda. C\u00f3rdoba S\/N , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-708X","authenticated-orcid":false,"given":"Alfredo","family":"Rodr\u00edguez-Antol\u00edn","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario 12 de Octubre , Avda. C\u00f3rdoba S\/N , Madrid, 28041,","place":["Spain"]},{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8075-0666","authenticated-orcid":false,"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-4709","authenticated-orcid":false,"given":"Santiago","family":"Ponce-Aix","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Scientific Coordinator\u2014Oncosur Foundation , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-3177","authenticated-orcid":false,"given":"Jes\u00fas M","family":"Paramio","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]},{"name":"Biomedical Research Center in Cancer Network (CIBERONC) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-1596","authenticated-orcid":false,"given":"Cristian","family":"Su\u00e1rez-Cabrera","sequence":"additional","affiliation":[{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]},{"name":"Biomedical Research Center in Cancer Network (CIBERONC) , Madrid,","place":["Spain"]},{"name":"Cellular and Molecular Oncology and Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario , 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-2297","authenticated-orcid":false,"given":"Carolina","family":"Rubio","sequence":"additional","affiliation":[{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]},{"name":"Cellular and Molecular Oncology and Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario , 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-1442","authenticated-orcid":false,"given":"Luc\u00eda","family":"Morales","sequence":"additional","affiliation":[{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-0626","authenticated-orcid":false,"given":"V\u00edctor","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]},{"name":"Biomedical Research Center in Cancer Network (CIBERONC) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-9726","authenticated-orcid":false,"given":"Marta","family":"Due\u00f1as","sequence":"additional","affiliation":[{"name":"Molecular and Translational Oncology Division, Biomedical Innovation Unit, Center for Energy, Environmental and Technological Research (CIEMAT) , Madrid,","place":["Spain"]},{"name":"Biomedical Research Center in Cancer Network (CIBERONC) , Madrid,","place":["Spain"]},{"name":"Cellular and Molecular Oncology and Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario , 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid, 28041,","place":["Spain"]},{"name":"Biomedical Research Center in Cancer Network (CIBERONC) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026060408391788500_oyag177-B1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/s0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2026060408391788500_oyag177-B2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"key":"2026060408391788500_oyag177-B3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s0140-6736(17)33297-x","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"2026060408391788500_oyag177-B4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus calmette-gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"2026060408391788500_oyag177-B5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.urolonc.2023.10.004","article-title":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L)1 inhibition","volume":"41","author":"Bedke","year":"2023","journal-title":"Urol Oncol"},{"key":"2026060408391788500_oyag177-B6","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/s0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"2026060408391788500_oyag177-B7","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"2026060408391788500_oyag177-B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"2026060408391788500_oyag177-B9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"2026060408391788500_oyag177-B10","author":"US Department of Health Human Services"},{"key":"2026060408391788500_oyag177-B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/pap.0000000000000118","article-title":"The paris system for reporting urinary cytology: the quest to develop a standardized terminology","volume":"23","author":"Barkan","year":"2016","journal-title":"Adv Anat Pathol"},{"key":"2026060408391788500_oyag177-B12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026060408391788500_oyag177-B13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"key":"2026060408391788500_oyag177-B14","author":"MedDRA"},{"key":"2026060408391788500_oyag177-B15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille calmette-gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026060408391788500_oyag177-B16","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/jco.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026060408391788500_oyag177-B17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus calmette-gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2026060408391788500_oyag177-B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ceor.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026060408391788500_oyag177-B19","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.3390\/ijms25063105","article-title":"Strategies for overcoming immune evasion in bladder cancer","volume":"25","author":"Shin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026060408391788500_oyag177-B20","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/jcm13144112","article-title":"Contemporary treatment of NMIBC-is it time to move on from BCG?","volume":"13","author":"Passarelli","year":"2024","journal-title":"J Clin Med"},{"key":"2026060408391788500_oyag177-B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00345-025-06180-5","article-title":"First-line treatments for BCG-na\u00efve non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"44","author":"Roessler","year":"2026","journal-title":"World J Urol"},{"key":"2026060408391788500_oyag177-B22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40487-025-00334-6","article-title":"On the horizon: a global multidisciplinary perspective on delivering emerging therapies for patients with BCG-na\u00efve high-risk NMIBC","volume":"13","author":"Szabados","year":"2025","journal-title":"Oncol Ther"},{"key":"2026060408391788500_oyag177-B23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.acuroe.2024.04.005","article-title":"Multidisciplinary consensus document on the current treatment of bacille Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder tumor","volume":"48","author":"Guerrero-Ramos","year":"2024","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"2026060408391788500_oyag177-B24","doi-asserted-by":"publisher","first-page":"e471912","DOI":"10.1200\/edbk-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026060408391788500_oyag177-B25","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"2026060408391788500_oyag177-B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2026.02.003","article-title":"Circulating plasma and urine tumor DNA in non\u2013muscle-invasive bladder cancer: a promising biomarker to guide therapeutic intensification","author":"Gabriel","year":"2026","journal-title":"Eur Urol Open Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag177\/68257222\/oyag177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag177\/68257222\/oyag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag177\/68257222\/oyag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:39:24Z","timestamp":1780576764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag177\/8674714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag177","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,8]]},"article-number":"oyag177"}}